LATEST UPDATES
Nestlé completes acquisition of The Bountiful Company core brands
Nestlé Health Science announces the successful completion of its acquisition of the core brands of The Bountiful Company , including Nature ’ s Bounty , Solgar , Osteo Bi-Flex , Puritan ’ s Pride , Ester-C and Sundown .
“ More people around the world are taking charge of their health , looking to vitamins , minerals , herbals and supplements to fill gaps or provide extra support ,” said Nestlé Health Science CEO , Greg Behar .
Don Kerrigan , President of North America for The Bountiful Company , will be joining Nestlé Health Science as the company ’ s new CEO of VMHS Health US , reporting to Greg Behar .
“ Today ’ s announcement marks an important milestone in The Bountiful Company ’ s journey and an exciting next phase for our well recognised , winning brands and the talented teams who have helped build them ,” said Kerrigan .
“ Today we ’ re pleased to welcome 4,000 new employees into Nestlé Health Science with our acquisition of the key brands from The Bountiful Company . The acquisition gives us a broader range of trusted products and more ways to enhance the health of customers around the world .”
Nestlé Health Science announced on April 30 , 2021 that it entered into an agreement to acquire the majority of The Bountiful Company ’ s brands . The closing of the deal establishes Nestlé Health Science as the industry leader in vitamins , minerals , herbals and supplements ( VMHS ) in mass retail , specialty retail , e-commerce and direct-to-consumer in the US , while providing new products and sales channels around the world .
Ping An-Shionogi joint venture launched in Shanghai , expanding footprint in healthcare industry
Ping An Insurance Group has announced that Ping An-Shionogi , a joint venture between Ping An and Shionogi & Co , has been launched in Shanghai .
Ping An-Shionogi is a Healthcare-as-a-Service ( HaaS ) enterprise , an integrated medical and healthcare platform , for public health and patients . The joint venture is a collaboration between the Ping An and Shionogi in drug research , development , production and sales .
It is based on Ping An ' s sophisticated healthcare ecosystem and advanced digital technology and Shionogi ’ s strengths in drug research and development . Using Ping An ' s leading healthtech capabilities , resources and advantages in insurance and financial services , and Shionogi ' s drug development capability and experience in the pharmaceutical industry , Ping An-Shionogi is committed to providing customers with personalised health management solutions , including exercise suggestions , medical prescriptions on over-the-counter drugs , vaccines , new drugs for different stages of healthcare including disease prevention , diagnosis , medical prescription and follow-up visits . It will create a new benchmark for the healthcare industry .
Ping An ' s strong digital capability is enabling Ping An-Shionogi to speed up drug development with data for specific diseases . It
also uses Shionogi ’ s pharmaceutical research centre to explore new drugs and conduct drug research and development in a more efficient and effective way .
Ping An-Shionogi will also draw on Ping An ’ s abundant medical resources to explore a new rapid clinical trial enrolment model to promote Shionogi ’ s development of new drugs in China . Two new types of drugs developed by Shionogi are being promoted according to the plan . x
10 www . intelligentcxo . com